YOU ARE NOW CONNECTED TO THE TOXLINE (1981 FORWARD, NON-ROYALTY) FILE.

                        ==LEIOMYOSARCOMA==

4
AUTHOR                    Schmal F
AUTHOR                    Laubert A
TITLE                     [Rare tumor of the nose and paranasal
                          sinuses. Leiomyosarcoma]
SOURCE                    HNO; VOL 43, ISS 4, 1995, P250-2 (REF: 22)
ABSTRACT                  Leiomyosarcoma is a rare malignant tumor of
                          the nose and paranasal sinuses. Including our
                          patient, 32 cases have been reported in the
                          literature. Radical surgery is currently the
                          best therapy. In comparison with results of
                          conventional irradiation, postoperative
                          neutron treatment appears to be more
                          effective.

7
AUTHOR                    Robinson M
AUTHOR                    Cassoni A
AUTHOR                    Harmer C
AUTHOR                    Fisher C
AUTHOR                    Thomas J
AUTHOR                    Westbury G
TITLE                     High dose hyperfractionated radiotherapy in
                          the treatment of extremity soft tissue
                          sarcomas.
SOURCE                    Radiother Oncol; VOL 22, ISS 2, 1991, P118-26
                          (REF: 42)
ABSTRACT                  A hyperfractionated radiotherapy schedule has
                          been evaluated in the treatment of 29 adults
                          with limb or limb girdle soft tissue
                          sarcomas. The objective was to increase the
                          total administered dose and possibly improve
                          local control, without increasing late normal
                          tissue damage. Twice daily 1.25 Gy fractions
                          (with a minimum interval of 6 h) have been
                          given over 5 to 6 weeks to 12 patients
                          pre-operatively, 10 post-operatively and 7
                          palliatively. Five patients received 62.5 Gy
                          in 5 weeks pre-operatively and 3
                          palliatively. Nineteen of the remaining 21
                          patients received 75 Gy in 6 weeks with a
                          field size reduction after 5 weeks. Sixteen
                          of 29 tumours were situated in the thigh and
                          only 2 were in the upper limb. Twenty were of
                          high grade. The mean tumour size of those
                          treated radically was 13.1 cm (range 5 to 40
                          cm). Sixteen patients (76%) given 75 Gy
                          developed moderate or severe skin erythema
                          maximal at 5 weeks. Despite the large field
                          sizes used (mean phase one of 34.5 cm, and
                          phase two of 22.8 cm) only 2 patients failed
                          to complete the planned treatment because of
                          the severity of these reactions. Two other
                          patients developed partial wound breakdowns
                          after the end of treatment--both healing
                          spontaneously. Fourteen patients developed an
                          area of moist desquamation--11 mild, 2
                          moderate and one severe. There have been four
                          late wound breakdowns requiring surgical
                          intervention; all have since healed well. The
                          median follow up is short at 556 days. Ten of
                          19 evaluable patients have developed
                          moderate/severe induration, 5/19 mild and
                          4/19 none.(ABSTRACT TRUNCATED AT 250 WORDS)

3
AUTHOR                    Sutton GP
AUTHOR                    Blessing JA
AUTHOR                    Barrett RJ
AUTHOR                    McGehee R
TITLE                     Phase II trial of ifosfamide and mesna in
                          leiomyosarcoma of the uterus: Gynecologic
                          Oncology Group study
SOURCE                    Am. J. Obstet. Gynecol.; VOL 166 ISS Feb
                          1992, P556-559, (REF 16)
ABSTRACT                  IPA  COPYRIGHT: ASHP  To evaluate the
                          efficacy of ifosfamide for advanced or
                          recurrent leiomyosarcoma, 35 patients (ages
                          32-65 yr) received 1.5 g/sq m/day of
                          intravenous ifosfamide for 5 days, every 4 wk
                          and those with prior radiotherapy received
                          1.2 g/sq m/day; 300 mg/sq m of intravenous
                          mesna was administered every 4 h for 3 doses
                          after each dose of ifosfamide. Results
                          indicated that 17.2% experienced partial
                          response and 28.6% had stable disease with
                          response durations ranging from 2.9 to 12.4
                          months. Toxic effects observed included grade
                          III or IV granulocytopenia (11%) and grade IV
                          neurotoxicity (2.8%). It was concluded that
                          ifosfamide has modest activity in patients
                          with advanced or current leiomyosarcomas of
                          the uterus.